BeiGene stock surges on EU approval for TEVIMBRA in advanced cancer treatment
BeiGene, a global oncology company, announced that the European Commission has granted regulatory approval for TEVIMBRA (tislelizumab), its PD-1 monoclonal antibody, for the first-line treatment ... Read More
Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. ... Read More
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round, bolstered by its key investors, argenx and ... Read More
Pharma breakthrough! BioIntelect to revolutionise trials using Opyl’s cutting-edge tech
In a landmark collaboration, Opyl Limited announced a new six-month agreement with BioIntelect, a renowned Clinical Research Organisation (CRO) and strategic consulting firm in the ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome
Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted both Rare Pediatric Disease designation and Orphan ... Read More
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its workforce by approximately 50%. This decision follows ... Read More
Is the cure for PTSD waiting in the wings? FDA says not yet!
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the use of MDMA, commonly known as ecstasy, ... Read More